{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T14:13:24Z","timestamp":1774966404254,"version":"3.50.1"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Shenzhen Salubris Pharmaceuticals Co., Ltd"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s40262-026-01622-8","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T09:06:44Z","timestamp":1770628004000},"page":"545-556","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacokinetics, Pharmacodynamics and Safety of Fultagliptin Benzoate Tablets, a DPP-4 Inhibitor, in Patients With Varying Degrees of Renal Insufficiency and Matched Healthy Volunteers: A Phase I Clinical Trial"],"prefix":"10.1007","volume":"65","clinical-trial-number":[{"clinical-trial-number":"nct06883656","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0390-4606","authenticated-orcid":false,"given":"Yue","family":"Chen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaotao","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuchun","family":"Men","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruijie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongyu","family":"Guan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lihong","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"Miao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,9]]},"reference":[{"key":"1622_CR1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m997","volume":"369","author":"Y Li","year":"2020","unstructured":"Li Y, Teng D, Shi X, et al. Prevalence of diabetes recorded in mainland China using 2018 diagnostic criteria from the American Diabetes Association: national cross sectional study. BMJ (Clin Res Ed). 2020;369:m997. https:\/\/doi.org\/10.1136\/bmj.m997.","journal-title":"BMJ (Clin Res Ed)"},{"issue":"2","key":"1622_CR2","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.ekir.2018.10.018","volume":"4","author":"JP Dias","year":"2019","unstructured":"Dias JP, Shardell M, Golden SH, et al. Racial\/ethnic trends in prevalence of diabetic kidney disease in the United States. Kidney Int Rep. 2019;4(2):334\u20137. https:\/\/doi.org\/10.1016\/j.ekir.2018.10.018.","journal-title":"Kidney Int Rep"},{"issue":"9818","key":"1622_CR3","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/S0140-6736(12)60033-6","volume":"379","author":"L Zhang","year":"2012","unstructured":"Zhang L, Wang F, Wang L, et al. Prevalence of chronic kidney disease in China: a cross-sectional survey. Lancet. 2012;379(9818):815\u201322. https:\/\/doi.org\/10.1016\/S0140-6736(12)60033-6.","journal-title":"Lancet"},{"issue":"6","key":"1622_CR4","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1001\/jama.2016.10924","volume":"316","author":"M Afkarian","year":"2016","unstructured":"Afkarian M, Zelnick LR, Hall YN, et al. Clinical manifestations of kidney disease among US adults with diabetes, 1988\u20132014. JAMA. 2016;316(6):602\u201310. https:\/\/doi.org\/10.1001\/jama.2016.10924.","journal-title":"JAMA"},{"key":"1622_CR5","doi-asserted-by":"publisher","unstructured":"Anonymous. KDIGO 2022 Clinical practice guideline for diabetes management in chronic kidney disease [J]. Kidney Int. 2022;102(5S):S1\u201327. https:\/\/doi.org\/10.1016\/j.kint.2022.06.008.","DOI":"10.1016\/j.kint.2022.06.008"},{"issue":"5","key":"1622_CR6","doi-asserted-by":"publisher","first-page":"658","DOI":"10.7326\/M23-2788","volume":"177","author":"A Qaseem","year":"2024","unstructured":"Qaseem A, Obley AJ, Shamliyan T, et al. Newer pharmacologic treatments in adults with type 2 diabetes: a clinical guideline from the American College of Physicians. Ann Intern Med. 2024;177(5):658\u201366. https:\/\/doi.org\/10.7326\/M23-2788.","journal-title":"Ann Intern Med"},{"issue":"1","key":"1622_CR7","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1159\/000339028","volume":"36","author":"B Hocher","year":"2012","unstructured":"Hocher B, Reichetzeder C, Alter ML. Renal and cardiac effects of DPP4 inhibitors\u2014from preclinical development to clinical research. Kidney Blood Press Res. 2012;36(1):65\u201384. https:\/\/doi.org\/10.1159\/000339028.","journal-title":"Kidney Blood Press Res"},{"issue":"1","key":"1622_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s13318-019-00570-y","volume":"45","author":"M Mikov","year":"2020","unstructured":"Mikov M, Pavlovi\u0107 N, Stanimirov B, et al. DPP-4 inhibitors: renoprotective potential and pharmacokinetics in type 2 diabetes mellitus patients with renal impairment. Eur J Drug Metab Pharmacokinet. 2020;45(1):1\u201314. https:\/\/doi.org\/10.1007\/s13318-019-00570-y.","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"6","key":"1622_CR9","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1080\/17425255.2021.1915283","volume":"17","author":"Y Ding","year":"2021","unstructured":"Ding Y, Zhang H, Li C, et al. Safety and pharmacokinetic interaction between Fotagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin in healthy subjects. Expert Opin Drug Metab Toxicol. 2021;17(6):725\u201331. https:\/\/doi.org\/10.1080\/17425255.2021.1915283.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"6","key":"1622_CR10","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1002\/cpdd.895","volume":"10","author":"M Wu","year":"2021","unstructured":"Wu M, Li QQ, Zhang H, et al. Safety, pharmacokinetics, and pharmacodynamics of a dipeptidyl peptidase-4 inhibitor: a randomized, double-blinded, placebo-controlled daily administration of Fotagliptin benzoate for 14 days for type 2 diabetes mellitus. Clin Pharmacol Drug Dev. 2021;10(6):660\u20138. https:\/\/doi.org\/10.1002\/cpdd.895.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"1","key":"1622_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12916-023-03089-x","volume":"21","author":"M Xu","year":"2023","unstructured":"Xu M, Sun K, Xu W, et al. Fotagliptin monotherapy with alogliptin as an active comparator in patients with uncontrolled type 2 diabetes mellitus: a randomized, multicenter, double-blind, placebo-controlled, phase 3 trial [J\/OL]. BMC Med. 2023;21(1):1\u201310. https:\/\/doi.org\/10.1186\/s12916-023-03089-x.","journal-title":"BMC Med"},{"key":"1622_CR12","unstructured":"European Medicines Agency. Guideline on the evaluation of the pharmacokinetics of medicinal products in patients with decreased renal function [R\/OL]. 2016. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-evaluation-pharmacokinetics-medicinal-products-patients-decreased-renal-function_en.pdf."},{"issue":"12","key":"1622_CR13","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1111\/j.1464-5491.2010.03131.x","volume":"27","author":"T Forst","year":"2010","unstructured":"Forst T, Uhlig-Laske B, Ring A, et al. Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled type 2 diabetes. Diabet Med. 2010;27(12):1409\u201319. https:\/\/doi.org\/10.1111\/j.1464-5491.2010.03131.x.","journal-title":"Diabet Med"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01622-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-026-01622-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01622-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T13:25:56Z","timestamp":1774963556000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-026-01622-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,9]]},"references-count":13,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["1622"],"URL":"https:\/\/doi.org\/10.1007\/s40262-026-01622-8","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,9]]},"assertion":[{"value":"19 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ruijie Zhang and Hongyu Guan reported being employed at Shenzhen Salubris Pharmaceuticals. The remaining authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The data that support the findings of this study are available from the corresponding authors upon reasonable request.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statement"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee for West China Hospital, Sichuan University (China).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all patients included in the study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by Jia Miao, Fang Liu, Chao Hu, Xiaotao Cao, Yuchun Men, and Ying Wang. The first draft of the manuscript was written by Yue Chen and Jia Miao, Ruijie Zhang, Hongyu Guan, and Lihong Shi commented on previous versions of the manuscript. All authors read and approved the final manuscript.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}